Announcement • Jul 31
AriBioLab Co.,Ltd. announced that it has received KRW 1.999999749 billion in funding On July 31, 2026, AriBioLab Co.,Ltd. has closed the transaction. Announcement • Jul 24
AriBioLab Co.,Ltd. announced that it expects to receive KRW 1.999999749 billion in funding from AriBio Co., Ltd. AriBioLab Co.,Ltd. announced a private placement to issue 942,063 shares at an issue price of KRW 2,123 per share for gross proceeds of KRW 1,999,999,749 on July 23, 2026. The transaction will include participation from new investor AriBio Co., Ltd. The transaction has been approved by shareholders, expected to close on July 31, 2026 and restricted to a hold period. Announcement • Jul 02
AriBioLab Co.,Ltd. announced that it has received KRW 2.999998825 billion in funding On June 30, 2026, AriBioLab Co.,Ltd. has closed the transaction. New Risk • May 29
New major risk - Revenue and earnings growth Earnings have declined by 0.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Revenue is less than US$1m (₩332m revenue, or US$222k). Minor Risk Market cap is less than US$100m (₩99.5b market cap, or US$66.6m). Announcement • May 15
CHA Vaccine Research Institute announced that it expects to receive KRW 4 billion in funding CHA Vaccine Research Institute has announced a private placement of Series 6 Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 4,000,000,000 on May 14, 2026. The transaction involves the new investor participation of Hanwool P&I Co., Ltd. for KRW 4,000,000,000. The bonds are 100% convertible into 1,246,105 common shares of the company at a conversion price value of KRW 3,210 and carry interest rate of 2% and maturity interest rate of 8%. The conversion billing period starts from June 05, 2027 to May 05, 2029.The transaction has been approved by the board of directors of the company. The transaction is subject to 1 year hold period. The bonds have a maturity date of June 05, 2029. The transaction is expected to close on June 05, 2026. New Risk • Apr 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (₩159m revenue, or US$107k). Minor Risk Market cap is less than US$100m (₩92.7b market cap, or US$62.6m). New Risk • Mar 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩159m revenue, or US$106k). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩142.4b market cap, or US$95.1m). Announcement • Mar 20
CHA Vaccine Research Institute announced that it expects to receive KRW 4.999999 billion in funding CHA Vaccine Research Institute announced a private placement to issue 1,834,862 common shares at an issue price of KRW 2,725 for gross proceeds of KRW 4,999,998,950 on March 18, 2026. The transaction includes participation from new investor, Dream High Holdings Co., Ltd. The transaction will happen through third party allocation. The transaction has been approved at board of director meeting of the company. The issue date will be May 29, 2026. The shares are subject to 1 year lockup. Announcement • Mar 12
CHA Vaccine Research Institute, Annual General Meeting, Mar 25, 2026 CHA Vaccine Research Institute, Annual General Meeting, Mar 25, 2026, at 09:01 Tokyo Standard Time. Location: conference hall, 808, seongnam-daero, bundang-gu, gyeonggi-do, seongnam South Korea Announcement • Mar 12
CHA Vaccine Research Institute, Annual General Meeting, Mar 26, 2025 CHA Vaccine Research Institute, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 808, seongnam-daero, bundang-gu, gyeonggi-do, seongnam South Korea New Risk • Jan 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩134.2b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩294m revenue, or US$219k). Minor Risk Market cap is less than US$100m (₩134.2b market cap, or US$99.7m). New Risk • Oct 18
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩131.0b (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩294m revenue, or US$217k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩131.0b market cap, or US$96.8m). New Risk • Jun 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩130.8b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 70% over the past year. Revenue is less than US$1m (₩184m revenue, or US$140k). Minor Risk Market cap is less than US$100m (₩130.8b market cap, or US$99.4m).